Nivix Pharmaceuticals Proposes 40 Percent Right Issue and Capital Expansion Ahead of IPO
28th September 2026, Kathmandu
Nivix Pharmaceuticals Limited has proposed issuing 40 percent right shares and expanding both its authorized and issued capital.
Nivix Pharmaceuticals Right Issue
According to the board of directors’ decision, a Special General Meeting (SGM) has been called for October 12, 2026 (Ashwin 26, 2083 BS) at Pokhara Event Centre in Bulaudi, Pokhara, starting at 11:00 AM to approve these capital restructure proposals.
Advertisement
Capital Enhancement and Right Share Terms
The company plans to significantly scale up its capital base through the upcoming right issue and subsequent capital adjustments.
- Capital Expansion: Authorized and issued capital will be increased from NPR 550 million to NPR 721.875 million (NPR 72.18 crore).
- Right Share Issuance: Proposal to issue 40 percent right shares based on the updated capital structure, alongside authorizing the board of directors to complete all necessary execution procedures.
- Promoter Share Ratio Adjustment: Promoter shareholder group ownership will be restructured from 75 percent to 80 percent.
- Initial Public Offering (IPO) Provision: The previous 25 percent public allocation will be adjusted to 20 percent of the revised issued capital, which will be offered to the general public via an Initial Public Offering (IPO).
- Articles and Memorandum Amendments: The board will receive complete authority to amend the Memorandum and Articles of Association to reflect the structural changes, capital growth, and public issue parameters.
For More: Nivix Pharmaceuticals Right Issue
